Outlook Therapeutics is trading 7.35% up now at $1.09, with the move appearing primarily technical and sentiment-driven following the July 24 FDA approval of LYTENAVA.

  • No new company-specific catalyst dated August 10 was identified.
  • The latest company release scheduled third-quarter results and a corporate update for August 14.
  • Broader markets are mixed and do not clearly explain the gain.